PR Newswire Clinical TrialsOriginal article
Karyopharm Submits Supplemental New Drug Application to the FDA for XPOVIO® (selinexor) Plus Ruxolitinib for Patients with Myelofibrosis
NDA FilingXPOVIOruxolitinibPositive
AI Analysis
Summary
Karyopharm Therapeutics submitted a supplemental NDA to the FDA for XPOVIO (selinexor) in combination with ruxolitinib for myelofibrosis patients under the Accelerated Approval Pathway with Priority Review requested.
Outcome Details
Supplemental New Drug Application submitted under Accelerated Approval Pathway with Priority Review requested
Importance:7/10
Sentiment:
0.60
FDAAccelerated ApprovalPriority ReviewCombination therapyMyelofibrosissNDA
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on August 31, 2026 11:30 AM